Hikma jumps 10% as brokers point to profit beat and undemanding rating

Hikma Pharmaceuticals shares jumped 10% to 1,721p after first-half results delivered profits ahead of expectations, marking the upside surprise as the key driver. Peel Hunt and Stifel both reaffirmed buy ratings, reinforcing a bullish near-term setup on the scale of the earnings beat.

Analysis

Hikma Pharmaceuticals shares jumped 10% to 1,721p after first-half results delivered profits ahead of expectations, marking the upside surprise as the key driver. Peel Hunt and Stifel both reaffirmed buy ratings, reinforcing a bullish near-term setup on the scale of the earnings beat.